SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rascalbythesea who wrote (902)2/12/1999 10:29:00 PM
From: Doug Bean   of 1837
 
Benny: I think it all depends on what this is really all about. if you recall, last time just before they turned cenestin down they came out with a couple of approvals for smaller drugs. I know if they give us a lesser drug in the next few days ,, i will be worried :-| I don't feel like 10 is a realistic figure ,, unless it is cenestin and then it probably would go much higher. Perhaps 7-8 will be it until something comes out, then it will be judged on what it is. I agree with you in that Earnings mean diddly squat right now but with one or two more secondary drugs they would become a profitable company and therein able to pursue approval for some time. i also agree that if it is institutions,, it is smaller ones.. But hey, if it is Censetin coming the big ones will be tipped off to it and we will know , when the big 100,000 share trades start to happen ( we should be so lucky) No i probably won't sell until the announcement.. i am one of those idiots that fall in love with a stock plus while 10 is good 15-20 is better :-)) CRDoug
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext